Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium

References

1. 1.↵
   1. Ostrom QT,
   2. Gittleman H,
   3. Truitt G, et al

   . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 2018;20:iv1–86 doi:10.1093/neuonc/noy131 pmid:30445539

   CrossRefPubMed
2. 2.↵
   1. Hargrave D,
   2. Bartels U,
   3. Bouffet E

   , Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006;7:241–48 doi:10.1016/S1470-2045(06)70615-5 pmid:16510333

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Gallitto M,
   2. Lazarev S,
   3. Wasserman I, et al

   . Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review. Adv Radiat Oncol 2019;4:520–31 doi:10.1016/j.adro.2019.03.009 pmid:31360809

   CrossRefPubMed
4. 4.↵
   1. Lemasson B,
   2. Wang H,
   3. Galban S, et al

   . Evaluation of concurrent radiation, temozolomide and ABT-888 treatment followed by maintenance therapy with temozolomide and ABT-888 in a genetically engineered glioblastoma mouse model. Neoplasia 2016;18:82–89 doi:10.1016/j.neo.2015.11.014 pmid:26936394

   CrossRefPubMed
5. 5.↵
   1. Yuan AL,
   2. Ricks CB,
   3. Bohm AK, et al

   . ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS One 2018;13:e0202860 doi:10.1371/journal.pone.0202860 pmid:30153289

   CrossRefPubMed
6. 6.↵
   1. Poussaint TY,
   2. Vajapeyam S,
   3. Ricci KI, et al

   . Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 2016;18:725–34 doi:10.1093/neuonc/nov256 pmid:26487690

   CrossRefPubMed
7. 7.↵
   1. Wan B,
   2. Wang S,
   3. Tu M, et al

   . The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression: a meta-analysis. Medicine (Baltimore) 2017;96:e6333 doi:10.1097/MD.0000000000006333 pmid:28296759

   CrossRefPubMed
8. 8.↵
   1. Calmon R,
   2. Puget S,
   3. Varlet P, et al

   . Multimodal magnetic resonance imaging of treatment-induced changes to diffuse infiltrating pontine gliomas in children and correlation to patient progression-free survival. Int J Radiat Oncol Biol Phys 2017;99:476–85 doi:10.1016/j.ijrobp.2017.04.007 pmid:28871999

   CrossRefPubMed
9. 9.↵
   1. Thomas AA,
   2. Arevalo-Perez J,
   3. Kaley T, et al

   . Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol 2015;125:183–90 doi:10.1007/s11060-015-1893-z pmid:26275367

   CrossRefPubMed
10. 10.↵
    1. Fram EK,
    2. Herfkens RJ,
    3. Johnson GA, et al

    . Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imaging 1987;5:201–08 doi:10.1016/0730-725X(87)90021-X pmid:3626789

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Tofts PS

    . Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91–101 doi:10.1002/jmri.1880070113 pmid:9039598

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Boxerman JL,
    2. Schmainda KM,
    3. Weisskoff RM

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67 pmid:16611779

    Abstract/FREE Full Text
13. 13.↵
    1. Jenkinson M,
    2. Bannister P,
    3. Brady M, et al

    . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41 doi:10.1006/nimg.2002.1132 pmid:12377157

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Jenkinson M,
    2. Beckmann CF,
    3. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90 doi:10.1016/j.neuroimage.2011.09.015 pmid:21979382

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Schindelin J,
    2. Arganda-Carreras I,
    3. Frise E, et al

    . Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676–82 doi:10.1038/nmeth.2019 pmid:22743772

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Strimmer K

    . fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics 2008;24:1461–62 doi:10.1093/bioinformatics/btn209 pmid:18441000

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Benjamini Y,
    2. Hochberg Y

    . Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological) 1995;57:289–300 doi:10.1111/j.2517-6161.1995.tb02031.x

    CrossRef
18. 18.↵
    1. Hargrave D,
    2. Chuang N,
    3. Bouffet E

    . Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 2008;86:313–19 doi:10.1007/s11060-007-9473-5 pmid:17909941

    CrossRefPubMed
19. 19.↵
    1. Kilburn LB,
    2. Kocak M,
    3. Baxter P, et al

    . A Pediatric Brain Tumor Consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer 2018;65 doi:10.1002/pbc.26832 pmid:29090526

    CrossRefPubMed
20. 20.↵
    1. Poussaint TY,
    2. Kocak M,
    3. Vajapeyam S, et al

    . MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol 2011;13:417–27 doi:10.1093/neuonc/noq200 pmid:21297126

    CrossRefPubMed
21. 21.↵
    1. Jansen MH,
    2. Veldhuijzen van Zanten SE,
    3. Sanchez Aliaga E, et al

    . Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol 2015;17:160–66 doi:10.1093/neuonc/nou104 pmid:24903904

    CrossRefPubMed
22. 22.↵
    1. Lobel U,
    2. Sedlacik J,
    3. Reddick WE, et al

    . Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 2011;32:315–22 doi:10.3174/ajnr.A2277 pmid:21087935

    Abstract/FREE Full Text
23. 23.↵
    1. Sedlacik J,
    2. Winchell A,
    3. Kocak M, et al

    . MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 2013;34:1450–55 doi:10.3174/ajnr.A3421 pmid:23436052

    Abstract/FREE Full Text
24. 24.↵
    1. Hipp SJ,
    2. Steffen-Smith E,
    3. Hammoud D, et al

    . Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro Oncol 2011;13:904–09 doi:10.1093/neuonc/nor076 pmid:21757444

    CrossRefPubMed
25. 25.↵
    1. Ceschin R,
    2. Kocak M,
    3. Vajapeyam S, et al

    . Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. J Neurooncol 2019;143:79–86 doi:10.1007/s11060-019-03133-y pmid:30810873

    CrossRefPubMed
26. 26.↵
    1. Lobel U,
    2. Hwang S,
    3. Edwards A, et al

    . Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic pontine gliomas during treatment: implications for current response assessment strategies. Neuroradiology 2016;58:1027–34 doi:10.1007/s00234-016-1724-8 pmid:27438806

    CrossRefPubMed
27. 27.↵
    1. Zukotynski K,
    2. Vajapeyam S,
    3. Fahey FH, et al

    . Correlation of 18F-FDG PET and MR apparent diffusion coefficient (ADC) histogram metrics with survival in diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium. J Nucl Med 2017;58:1264–69 doi:10.2967/jnumed.116.185389 pmid:28360212

    Abstract/FREE Full Text
28. 28.↵
    1. Lober RM,
    2. Cho YJ,
    3. Tang Y, et al

    . Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neurooncol 2014;117:175–82 doi:10.1007/s11060-014-1375-8 pmid:24522717

    CrossRefPubMed
29. 29.↵
    1. Castel D,
    2. Philippe C,
    3. Calmon R, et al

    . Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 2015;130:815–27 doi:10.1007/s00401-015-1478-0 pmid:26399631

    CrossRefPubMed
30. 30.↵
    1. Vajapeyam S,
    2. Stamoulis C,
    3. Ricci K, et al

    . Automated processing of dynamic contrast-enhanced MRI: correlation of advanced pharmacokinetic metrics with tumor grade in pediatric brain tumors. AJNR Am J Neuroradiol 2017;38:170–75 doi:10.3174/ajnr.A4949 pmid:27633807

    Abstract/FREE Full Text
31. 31.↵
    1. Conway AE,
    2. Reddick WE,
    3. Li Y, et al

    . “Occult” post-contrast signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis? Neuroradiology 2014;56:405–12 doi:10.1007/s00234-014-1348-9 pmid:24626721

    CrossRefPubMed
32. 32.↵
    1. Kilday JP,
    2. Pringle C,
    3. Kamaly-Asl ID, et al

    . RADI-15: perfusion imaging in presumed pediatric diffuse intrinsic pontine glioma: a UK regional analysis. Neuro Oncol 2018;20(Suppl 2):i172–73 doi:10.1093/neuonc/noy059.655

    CrossRef
33. 33.↵
    1. Zikou A,
    2. Sioka C,
    3. Alexiou GA, et al

    . Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol Imaging 2018;2018:6828396 doi:10.1155/2018/6828396 pmid:30627060

    CrossRefPubMed
34. 34.↵
    1. Chassot A,
    2. Canale S,
    3. Varlet P, et al

    . Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 2012;106:399–407 doi:10.1007/s11060-011-0681-7 pmid:21858607

    CrossRefPubMed
35. 35.↵
    1. Carceller F,
    2. Fowkes LA,
    3. Khabra K, et al

    . Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. J Neurooncol 2016;129:109–21 doi:10.1007/s11060-016-2151-8 pmid:27180091

    CrossRefPubMed
36. 36.↵
    1. Ceschin R,
    2. Kurland BF,
    3. Abberbock SR, et al

    . Parametric response mapping of apparent diffusion coefficient as an imaging biomarker to distinguish pseudoprogression from true tumor progression in peptide-based vaccine therapy for pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 2015;36:2170–76 doi:10.3174/ajnr.A4428 pmid:26338910

    Abstract/FREE Full Text
37. 37.↵
    1. Calmon R,
    2. Puget S,
    3. Varlet P, et al

    . Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas. Neuro Oncol 2018;20:994–1002 doi:10.1093/neuonc/nox227 pmid:29244086

    CrossRefPubMed
38. 38.↵
    1. Carceller F,
    2. Jerome NP,
    3. Fowkes LA, et al

    . Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas. Pediatr Hematol Oncol 2019;36:103–12 doi:10.1080/08880018.2019.1592267 pmid:30978130

    CrossRefPubMed
39. 39.↵
    1. Song YS,
    2. Choi SH,
    3. Park CK, et al

    . True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. Korean J Radiol 2013;14:662–72 doi:10.3348/kjr.2013.14.4.662 pmid:23901325

    CrossRefPubMedWeb of Science